Skip to content
10-Q

Quarterly Report

SIGYN THERAPEUTICS, INC. SIGY

0001493152-24-033048

← back to feed
Filed
Aug 19, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 14, 2024 1.26M sh
Long Term Debt Q2 2024 · Jun 30, 2024 $2.01M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $53.64K
Cash And Equivalents Q2 2024 · Dec 31, 2023 $11.69K
Current Liabilities Q2 2024 · Jun 30, 2024 $3.9M
Current Liabilities Q2 2024 · Dec 31, 2023 $3.61M
Total Liabilities Q2 2024 · Jun 30, 2024 $3.99M
Total Liabilities Q2 2024 · Dec 31, 2023 $3.73M
Current Assets Q2 2024 · Jun 30, 2024 $146.38K
Current Assets Q2 2024 · Dec 31, 2023 $118.06K
Total Assets Q2 2024 · Jun 30, 2024 $320.17K
Total Assets Q2 2024 · Dec 31, 2023 $321.81K
Shares Diluted restated Q2 2024 · Jun 30, 2023 1.08M sh
Shares Diluted restated Q2 2024 · Jun 30, 2023 1.02M sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$891.27K
Stockholders Equity restated Q2 2024 · Jun 30, 2023 −$3.04M
Stockholders Equity restated Q2 2024 · Mar 31, 2023 −$2.35M
Stockholders Equity restated Q2 2024 · Dec 31, 2022 −$1.9M
Eps Diluted restated Q2 2024 · Jun 30, 2023 −$0.67
Eps Diluted restated Q2 2024 · Jun 30, 2023 −$2.02
Eps Basic restated Q2 2024 · Jun 30, 2023 −$0.67
Eps Basic restated Q2 2024 · Jun 30, 2023 −$2.02
Sga Expense Q2 2024 · Jun 30, 2023 $317.25K
Sga Expense Q2 2024 · Jun 30, 2023 $652.98K
Rd Expense Q2 2024 · Jun 30, 2023 $219.16K
Rd Expense Q2 2024 · Jun 30, 2023 $367K
Net Income Q2 2024 · Jun 30, 2023 −$723.12K
Net Income Q2 2024 · Jun 30, 2023 −$2.06M
Net Income Q2 2024 · Mar 31, 2023 −$1.34M
Operating Income Q2 2024 · Jun 30, 2023 −$574.01K
Operating Income Q2 2024 · Jun 30, 2023 −$1.1M